ライフサイエンスコーパス: zoledronate

1 0.5 microM for the bisphosphonate inhibitor, zoledronate).

2 f animals with vehicle, OPG, alendronate, or zoledronate.

3 ased by OPG but not by either alendronate or zoledronate.

4 sites, with a significant positive effect of zoledronate.

5 ighly active species such as minodronate and zoledronate.

6 were not augmented by adding pravastatin and zoledronate.

7 Eight of 1001 subjects receiving zoledronate (0.8%) exhibited mild to severe AAU within 7

8 In contrast, treatment with zoledronate (100 microM) did not induce cell death, inst

9 ANK-Fc; 100 microg of OPG-Fc; or 5 microg of zoledronate 2 h before 1,25(OH)(2)D(3) challenge on day

10 Intravenous infusion of zoledronate 5 mg or placebo.

11 AAU occurring after intravenous infusion of zoledronate (5 mg).

12 T cells, a phenomenon strongly augmented by zoledronate, a farnesyl pyrophosphate synthase inhibitor

13 Zoledronate activates human Vgamma9Vdelta2 T cells, whic

14 dard adjuvant systemic therapy alone or with zoledronate administered at a dose of 4 mg for 19 doses

15 Ten years after trial initiation, zoledronate administered at baseline and 5 years was eff

16 Whether infrequent zoledronate administration would prevent vertebral fract

17 In addition, zoledronate affected the deposition of collagen in TEVGs

18 like model was created by treating rats with zoledronate and dexamethasone, extracting teeth, and imm

19 ophilic analogs of the bone-resorption drugs zoledronate and risedronate.

20 T lymphocytes by synthetic phosphoantigens, zoledronate, and a BTN3A1 Ab in the absence of an exogen

21 tivation of Vgamma9Vdelta2 T cells by HMBPP, zoledronate, and POM2-C-HMBP, but not by a partial agoni

22 e-chain 2H-labeled pamidronate, alendronate, zoledronate, and risedronate on bone show that all side

23 HsFPPS with taxodione+zoledronate, arenarone+zoledronate, and taxodione alone.

24 ion concentrations, whereas pamidronate and zoledronate appear to act on the hFOB cells by a direct

25 Bisphosphonates such as alendronate and zoledronate are blockbuster drugs used to inhibit osteoc

26 crystal structures of HsFPPS with taxodione+zoledronate, arenarone+zoledronate, and taxodione alone.

27 All cases of AAU were from the zoledronate arm of the study, where the incidence was 0.

28 In the zoledronate arm, high CD73 score did not have associatio

29 idence of 2.1% (95% CI, 0.9% to 3.3%) in the zoledronate arm.

30 randomly assigned to receive an infusion of zoledronate at a dose of 5 mg at baseline and at 5 years

31 at 5 years (zoledronate-zoledronate group), zoledronate at a dose of 5 mg at baseline and placebo at

32 armacologic inhibition of bone resorption by zoledronate attenuates inflammasome activation in mice.

33 either 30- micro g or 150- micro g doses of zoledronate before tumor implantation (pretreatment grou

34 P) site, not to the allosteric site, whereas zoledronate bound via Mg(2+) to the same site as seen in

35 uptake of AF-ALN or internalization of [14C]zoledronate but prevented the inhibitory effect of alend

36 Likewise, zoledronate caused a substantial delay in gammadelta T c

37 (EDTA)-demineralized dentin with or without zoledronate-containing primer (Zol-primer) pre-treatment

38 In the zoledronate-containing structures, taxodione and arenaro

39 stemic administration of the bisphosphonate, zoledronate, could prevent bone lysis and halt the proli

40 Pamidronate and zoledronate decreased hFOB cell proliferation with equal

41 acid phosphatase (TRAP) staining showed that zoledronate decreased osteoclastic numbers and that ther

42 Zoledronate did not affect the in vitro proliferation of

43 t central skeleton trabecular bone loss, and zoledronate does not induce ABD.

44 y suggest that treatment with pamidronate or zoledronate enhances the differentiation and bone-formin

45 d trial to assess the safety and efficacy of zoledronate for preventing bone loss in the first year a

46 trabecular connectivity (and no benefit from zoledronate); HR-pQCT detected trabecular bone loss at t

47 f this study was to evaluate the efficacy of zoledronate in limiting the formation and/or progression

48 Both pamidronate and zoledronate increase hFOB cell bone formation, whereas n

49 memory phenotype, were sufficient to enable zoledronate-induced expansion of highly purified gammade

50 IL-18 was shown to enhance zoledronate-induced gammadelta T cell activation.

51 he potent nitrogen-containing bisphosphonate zoledronate inhibits farnesyl pyrophosphate synthase, a

52 However, zoledronate is associated with the occasional developmen

53 enced decreased bone turnover after KTx, but zoledronate itself did not affect this outcome.

54 While zoledronate led to a decrease in the number of macrophag

55 rly breast cancer, adjuvant zoledronic acid (zoledronate) may reduce recurrence and improve survival.

56 Newer generation bisphosphonates, such as zoledronate, may have differential effects on graft deve

57 eridronate (n = 5), pamidronate (n = 1), and zoledronate (n = 2), were included.

58 dronate (n = 17) and pamidronate followed by zoledronate (n = 33).

59 Bisphosphonate therapy included zoledronate (n = 34) or pamidronate (n = 17) and pamidro

60 In conclusion, zoledronate offers an additional inhibitory effect to th

61 nted the inhibitory effect of alendronate or zoledronate on Rap1A prenylation.

62 We sought to examine the effect of zoledronate on TEVG neotissue formation and its potentia

63 ed by OPG treatment, whereas alendronate and zoledronate only partially reduced these two parameters.

64 the Vgamma9(+) T cells in medium containing zoledronate or IPP strongly increased SF-derived fibrobl

65 Thus, mice implanted with TEVGs received zoledronate or no treatment and were monitored by serial

66 zed 34 patients before transplant to receive zoledronate or no treatment.

67 s, similar to those observed with OPG-Fc and zoledronate (p < or = 0.01 vs controls).

68 ction (P = .009), treatment with pamidronate/zoledronate (P = .009), longer follow-up time (P = .03),

69 bone loss at the peripheral skeleton, which zoledronate partially attenuated.

70 s on Oral-QoL differed significantly between zoledronate patients and control patients.

71 of 5 mg at baseline and placebo at 5 years (zoledronate-placebo group), or placebo at both baseline

72 zoledronate group, in 23 women (6.6%) in the zoledronate-placebo group, and in 39 women (11.1%) in th

73 interval {CI}, 0.34 to 0.92; P = 0.04]; and zoledronate-placebo vs. placebo-placebo, 0.59 [95% CI, 0

74 1 (95% CI, 0.51 to 0.99), respectively, when zoledronate-placebo was compared with placebo-placebo.

75 Zoledronate prevents fractures in older women when admin

76 The in vivo administration of zoledronate produced significant bone preservation but d

77 , DU145, and LNCaP cells with pamidronate or zoledronate significantly reduced the growth of all thre

78 nd to the same site as seen in the taxodione+zoledronate structure, but the second located to a more

79 rophosphate and the aminobisphosphonate drug zoledronate that causes intracellular accumulation of is

80 d bisphosphonate inhibitors, alendronate and zoledronate, that inhibit the consumption of DMADP and I

81 Zoledronate therapy deters whereas PTH therapy promotes

82 er, repletion of GGPP, which prevented acute zoledronate toxicity, and supplementation with IL-18, wh

83 TEVGs from zoledronate-treated mice demonstrated a significantly gr

84 sible cases of ONJ were reported, all in the zoledronate-treated patients.

85 derwent a second randomization of 5 years of zoledronate treatment (4 mg intravenously every 3 months

86 ly every 6 months for 3 years) vs 2 years of zoledronate treatment (4 mg intravenously every 3 months

87 ere measured from 2 years after the start of zoledronate treatment (landmark analysis).

88 ften in the 5-year (46.2%) vs 2-year (27.2%) zoledronate treatment arm, which was particularly true f

89 d clinical trial indicate that extending the zoledronate treatment beyond 2 years does not improve th

90 Zoledronate treatment demonstrates that the process of s

91 erial (polyglycolic-acid) were higher in the zoledronate treatment group.

92 otassium etidronate dihydrate and monosodium zoledronate trihydrate.

93 man enzyme in complexes with risedronate and zoledronate, two of the leading N-BPs in clinical use.

94 Adjuvant zoledronate used in the intensive schedule studied in th

95 r transferrin), and uptake of AF-ALN or [14C]zoledronate was inhibited by dansylcadaverine, indicatin

96 cancer cell growth in the presence of serum, zoledronate was more potent under these conditions, disr

97 tibias implanted with the LAPC-9 cells, the zoledronate was not effective in halting the formation o

98 rabbit osteoclasts; uptake of AF-ALN or [14C]zoledronate was stimulated by the presence of Ca2+ and S

99 The zoledronate was very effective in limiting the formation

100 cting etidronate and the potent new analogue zoledronate, were also compared with the action of pamid

101 The most active compounds were found to be zoledronate (whose single-crystal X-ray structure is rep

102 The systemic administration of zoledronate with STI571 and paclitaxel produced a signif

103 imarily neutral pyridine side chain, whereas zoledronate (with an imidazole ring) binds more strongly

104 tion inhibitors lonafarnib+/-pravastatin and zoledronate, within 3 sequential open-label clinical tri

105 during early stages of MRONJ development in zoledronate (ZA)-treated mice with periodontal disease a

106 We tested whether zoledronate (Zol) treatment impaired dendritic cell (DC)

107 Zoledronate (ZOL) treatment induces intracellular accumu

108 Here, we studied fluvastatin (Fluva) and zoledronate (Zol), representative molecules of each clas

109 chimeric antigen receptor (CAR) T cells and zoledronate (ZOL).

110 ey rats (n = 30), and either bisphosphonate (zoledronate [Zol]), PTH, or saline (vehicle control [VC]

111 t a dose of 5 mg at baseline and at 5 years (zoledronate-zoledronate group), zoledronate at a dose of

112 fracture occurred in 22 women (6.3%) in the zoledronate-zoledronate group, in 23 women (6.6%) in the

113 in the placebo-placebo group (relative risk, zoledronate-zoledronate vs. placebo-placebo, 0.56 [95% c

114 0 (95% CI, 0.42 to 0.86), respectively, when zoledronate-zoledronate was compared with placebo-placeb